What is Xavron?
Xavron is a prescription drug product indicated for early empirical treatment of acute ischemic stroke or for the treatment of amyotrophic lateral sclerosis. According to the mechanism of action, Xavron is a blocker of the ischemic cascade. It is noteworthy that in acute coronary syndrome also develops an ischemic cascade, which is similar to the ischemic cascade on the background of ischemic stroke.
What is the active substance of Xavron?
The active substance of Xavron is edaravone, a compound created by Japanese scientists for the treatment of neurological diseases. Since 2009, edaravone has been included in the Japanese protocol for the treatment of acute ischemic stroke (grade B).
How to use Xavron in acute coronary syndrome?
Xavron in acute coronary syndrome must be used on prescription. There are two schemes of application of Xavron depending on the reperfusion.
- If reperfusion is planned, the first dose (30 mg / 1 amp.) of Xavron is administered intravenously within 10 minutes immediately before reperfusion. Then move on to the scheme of 30 mg / 1 amp. intravenously (the contents of the ampoule should be dissolved in 100 ml of 0.9% sodium chloride solution) twice a day for up to 14 days.
- If reperfusion is not planned, Xavron is administered from the moment of hospitalization at 30 mg / 1 amp. intravenously (the contents of the ampoule should be dissolved in 100 ml of 0.9% sodium chloride solution) twice a day for up to 14 days.
How to evaluate the effectiveness of treatment of acute coronary syndrome with Xavron?
In acute coronary syndrome, edaravone (Xavron) reduces the risk of reperfusion arrhythmias, increases the ejection fraction of the left ventricle, reduces the enzymatic size of myocardial infarction, and reduces the risk of re-hospitalization due to repeated acute coronary syndrome within 12 months.
In which countries is Xavron (edaravone) used to treat acute coronary syndrome?
Xavron (or edaravone under other trade names) is currently used in Japan, China, Uzbekistan, Tajikistan and Ukraine to treat acute coronary syndrome.
Who should not take Xavron?
Contraindications to the administration of Xavron are:
- Severe renal failure.
- Hypersensitivity to the components of the product.
What is the dosage form of Xavron?
Xavron is available in ampoules of 20 ml. Each ampoule contains 30 mg of edaravone. 2 or 10 ampoules per pack.